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ABSTRACT
Acute myeloid leukemia (AML) cells induce, in vitro, NK cell abnormalities 
(NKCAs) including apoptosis and activating receptor down-regulation. The potential 
negative impact of AML cells on the therapeutic efficacy of NK cell-based strategies 
prompted us to analyze the mechanisms underlying NKCAs and to develop approaches 
to protect NK cells from NKCAs. NKCA induction by the AML leukemia cells target 
a subpopulation of peripheral blood NK cells and is interleukin-2 independent 
but is abrogated by a long-term culture of NK (LTNK) cells at 37°C. LTNK cells 
displayed a significantly enhanced ability to damage AML cells in vitro and inhibited 
the subcutaneous growth of ML-2 cells grafted into CB17 SCID mice. Actinomycin 
D restored the susceptibility of LTNK cells to NKCAs while TAPI-0, a functional analog 
of the tissue inhibitor of metalloproteinase (TIMP) 3, inhibits ML-2 cell-induced 
NKCAs suggesting that the generation of NK cell resistance to NKCAs involves RNA 
transcription and metalloproteinase (MPP) inactivation. This conclusion is supported 
by the reduced susceptibility to AML cell-induced NKCAs of LTNK cells in which TIMP3 
gene and protein are over-expressed. This information may contribute to the rational 
design of targeted strategies to enhance the efficacy of NK cell-based-immunotherapy 
of AML with haploidentical NK cells.
INTRODUCTION
Growing clinical evidence indicates that 
immunotherapy with NK cells is useful in the treatment of 
myeloid leukemia. However, in the majority of patients, 
the efficacy of this therapy is limited since the clinical 
responses are not always complete, or the disease recurs.
[1–7] These clinical findings have prompted investigators 
to characterize the interactions of NK cells with AML 
cells, since the resulting information may contribute to 
the rationale design of strategies to optimize the efficacy 
of NK cell-based immunotherapy of AML. Convincing 
experimental and clinical evidence indicates that AML 
cells damage NK cells; this damage reduces the ability of 
NK cells to control AML cell growth and provides AML 
cells with the capacity to escape from NK cell immunity. 
The damages induced by AML cells to NK cells both in 
vitro and in vivo are referred to as NKCAs; they include 
apoptosis[8], defective expression and function of natural 
cytotoxic receptors (NCRs), [9, 10] and CD16 down-
regulation. Scant information is available about the 
mechanism(s) underlying the induction of NKCAs by 
AML cells; although, this information may contribute to 
the rationale design of strategies to inhibit or counteract 
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their induction. Therefore, in this study guided by the 
notion that MMP chemical inhibitors reverse CD16 
down-regulation,[11] induced by AML cells, we have 
investigated whether MMP endogenous inhibitors are 
involved in the inhibition of AML cell-induced CD16 
down-regulation. Furthermore, because of the association 
of CD16 cross-linking by mAb with the induction of NK 
cell apoptosis,[12] we have investigated the role of CD16 
in the induction of AML-cell induced NK cell apoptosis 
and depletion. Lastly, taking advantage of the information 
generated by these experiments, we have developed 
a strategy to counteract the induction of NKCAs by 
leukemia cells.
RESULTS
NKCA induction by AML cells
Incubation of peripheral blood mononuclear cells 
(PBMCs) with the human AML cell line, ML-2, for 5 
hours at 37°C induced: 1) CD16 down-regulation on NK 
cells; 2) apoptosis of NK cells as indicated by an increased 
frequency of Annexin-V+ NK cells as compared to the 
PBMCs incubated without the leukemic cell line and 3) 
depletion of NK cells as shown by a reduction in their 
number as compared to that in PBMCs incubated without 
the leukemia cell line. Similar results were obtained when 
Figure 1: Human AML cell-induced NKCAs involves CD16 antigen. Panel A. PBMCs from healthy donors were cultured 
for 3 days in the presence of IL-2. Cells were then harvested and incubated with AML cells at a ratio of 4 PBMCs to 1 AML cell. 
PBMCs incubated under the same experimental conditions, but without AML cells were used as controls. Following a 5-hour incubation 
at 37°C, cells were stained with FITC-annexin-V, PE-anti-CD16, PE-Cy5-anti-CD3, APC-anti-CD56 and analyzed utilizing a 2-laser flow 
cytometer. We assessed the effects of AML cells on CD16 mean fluorescence intensity (MFI), NK cell apoptosis, and NK cell depletion by 
designing an electronic gate on CD16+CD56+CD3- cells. This figure shows data obtained from 6 experiments independently performed. 
Panel B. Following a 3-day activation with IL-2, PBMCs were harvested, and NK cells were negatively sorted using immunomagnetic 
beads. NK cells were then incubated in the absence (panel B, upper left) or presence (panel B, lower left) of ML-2 cells. NK cells were 
incubated at room temperature for 30 min in the presence of the indicated anti-CD157 mAb with or without ML-2 cells then washed. 
Quadrant numbers indicate CD16 MFI. Following a 5-hour incubation CD16 and CD56 antigens and annexin-V were evaluated by flow 
cytometry. Panel C. shows differential expression of annexin-V on NK cells stimulated as indicated. This figure shows a representative 
experiment out of 3 performed with similar results.
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the AML cell lines THP-1 and U937 were used; although, 
with some differences in the extent of changes. THP-1 cells 
were significantly less potent inducers of NKCAs than ML-2 
and U937 cell lines (Figure 1A). The latter two cell lines 
did not differ from each other. The extent of the NKCAs 
induced by leukemia cells was markedly increased when 
NK cells incubated with leukemia cells were activated by 
cross-linking of CD16 mediated by its interaction with the 
Fc fragment of the CD157-specific mAb SY11B5. CD157 
is expressed on leukemia cells but is not detectable on NK 
cells. These findings raise the possibility that CD16 plays a 
role in the induction of NKCAs by leukemic cells.
CD16 involvement in the induction of NKCAs by 
AML cells
To investigate a cause-effect relationship between 
CD16 down-regulation and induction of NKCAs by 
leukemia cells, CD16 was cross-linked by incubating 
IL-2 stimulated short term NK (STNK) cells for 5 hours 
at 37°C with ML-2 cells coated with the CD157-specific 
mAb SY11B5. Although with some differences in the 
degree of changes, mAb SY11B5 enhanced ML-2 cell-
induced CD16 down-regulation (Figure 1 panel B) and 
extent of apoptosis (Figure 1 panel C). The highest level of 
NKCAs was observed when NK cells were incubated with 
ML-2 cells and mAb SY11B5. Similar results were also 
obtained with U937 cells (data not shown). These findings 
are compatible with the possibility that CD16 antigen 
plays a role in the induction of NKCAs by leukemia 
cells. Additional evidence in support of this possibility is 
provided by CD16 higher expression on STNK than on 
LTNK cells (data not shown).
Generation by long-term in vitro culture of NK 
cell resistance to leukemia cell-induced NKCAs
To determine whether the duration of IL-2 
incubation with NK cells affected their susceptibility 
to NKCAs, we investigated the effect of ML-2 cells on 
STNK and LTNK cell cultures. Figure 2 shows that STNK 
cells were susceptible to AML cell-induced NKCAs as 
indicated by a marked CD16 down-regulation (Figure 2, 
upper, right panel), depletion of CD16+ cells (Figure 2, 
lower, right panel) and induction of apoptosis of CD16+ 
and CD16- NK cells (Figure 2, lower, left panel). In 
contrast, LTNK cells that displayed a strong lytic activity 
(Figure 2, upper left, panel) were resistant to leukemia 
cell-induced NKCAs. This conclusion is indicated by the 
lack of significant difference between NK cells incubated 
with ML-2 and control NK cells incubated without ML-2 
cells to the extent of CD16 down-regulation as well as cell 
apoptosis. These results indicate that long-term in vitro 
culture of NK cells reduces their susceptibility to AML 
cell-induced NKCAs. Similar results were obtained also 
when STNK and LTNK cells were tested for their ability 
Figure 2: Long-term culture condition protects NK cells, in vitro, from ML-2 cell-induced NKCAs. Following a 3 or 
a 10-day activation with IL-2, NK cells were incubated for 4 hours at 37°C with 51Cr-labelled ML-2 cells at the indicated E/T cell ratio 
(upper, left panel). For NKCAs: IL-2 stimulated PBMCs were cultured in the absence or presence of ML-2 at 4:1 E/T ratio. CD16MFI of 
NK cells (upper, right panel), percentage of apoptosis (lower, left panel) and percentage of NK cells (lower, right panel) were evaluated in 
the CD16+NK and CD16-NK cell subsets by flow cytometry.
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to lyse the leukemia cell lines THP-1 and U937 and their 
susceptibility to induction of NKCAs by these leukemia 
cell lines (data not shown).
To determine the extent of damage induced by 
ML-2 cells in STNK and LTNK cells both types of cells 
were subjected to 2-consecutive rounds incubation, the 
extent of damage induced in STNK cells by ML-2 cells 
was significantly lower than that induced following the 
first incubation with ML-2 cells (Figure 3, panels B, and 
C). The reduced susceptibility of ML-2 cell-induced 
NKCAs of STNK cells was associated with a decreased 
anti-leukemia activity (Figure 3D, upper and lower left 
panels). In contrast, following both the first and second 
incubation, with ML-2 cells, LTNK cells were resistant 
to ML-2 cells, and were effective in inducing damage 
of ML-2 cells (Figure 3D, upper and lower right panels) 
suggesting that ML-2 cells reduce the frequency of 
STNK effector cells following their first incubation. Also, 
following their first incubation with IL-2 cells, viable 
STNK and LTNK cells, sorted from the NK and ML-2 
cell preparation, induced a similar extent of ML-2 cell-
damage (Figure 3, panel E). These results suggest that 
STNK cells are composed of at least two subpopulations: 
one susceptible and the other one resistant to ML-2 cell 
induced NKCAs.
Inhibition by LTNK cells of ML-2 cell growth in 
CB17 scid mice
To compare the ability of LTNK and STNK cells 
to inhibit the subcutaneous growth of leukemia cells, 
ML-2 cells were mixed with LTNK cells or STNK cells 
and injected subcutaneously into CB17-scid mice. ML-2 
cells injected into mice without NK cells were used as 
a reference control. LTNK cells significantly inhibited 
leukemia cell growth (P = 0.001) while STNK cells did 
not (Figure 4A). In addition, LTNK cells significantly 
prolonged disease free survival (DFS) (P = 0.03) and 
overall survival (OS) (P = 0.01) of leukemia bearing 
mice as compared to STNK cells (Figure 4, 4B, and 
4C).These data suggest that LTNK cell treatment is 
associated with a favorable clinical course of the disease.
Figure 3: ML-2 cells reduces, in vitro, the frequency of short-term NK effector cells with anti-leukemia activity. IL-2 
post-activated STNK and LTNK cells were subjected to a 2 consecutive rounds of incubation with ML-2 cells at a ratio of 4 STNK or 
LTNK cells to 1 ML-2 cell at 37°C. Following a 5-hour and an 18-hour incubation of STNK and LTNK cells with ML-2 cells, cell aliquots 
were harvested and stained with FITC-annexin-V, PI, PE-anti-CD16, and APC-anti-CD56 and analyzed by flow cytometry for CD16 
down-regulation panel A., NK cell apoptosis panel B., NK cell depletion panel C. and ML-2 cell damage panel D. Also, following the first 
incubation with ML-2 cells, STNK and LTNK cells were magnetically sorted from cell preparations and reincubated overnight with ML-2 
cells at 37°C. Then, cells were stained with FITC-annexin-V and PI and analyzed by flow cytometry. ML-2 cells were identified by posting 
an electronic gate on cells with the highest forward and side scatters panel E.
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Resistance to AML cell-induced NKCAs in the 
long-term culture setting is IL-2 independent 
and is in part mediated by MMPs inhibited by 
TIMP3
To investigate whether RNA transcription is 
involved in the generation of NK cell resistance to 
NKCAs, we tested the effect of actinomycin D on LTNK 
cell culture. We utilized 10 ng/ml of actinomycin D 
since this concentration did not affect the expression of 
CD16 and the percentage of NK cells present in PBMC 
preparations. Table 1 shows that following a 3-day culture 
with ML-2 cells, STNK cells underwent NKCAs and 
following a 10-day culture, LTNK cells became NKCA 
resistant. In contrast, ML-2 cells induced a significant 
down-regulation of CD16 expression (P = 0.004) and a 
trend toward significant reduction in the NK cell number 
(P = 0.09) in the PBMC preparations cultured in the 
presence of actinomycin D. These results suggest that NK 
cell RNA transcription is involved in the generation of 
AML cell-induced NKCA.
MMP activation during NK cell/leukemia cell 
conjugation has been recently shown to cause CD16 
down-regulation in resting NK cells. Consistent with 
this result, chemical inhibitors of MMPs have been 
shown to inhibit CD16 down-regulation induced by 
AML cells.[11] This finding provided us with the 
rationale to test whether TIMP3, a potent endogenous 
MMP inhibitor is involved in the inhibition of NKCA 
induction by AML cells. To investigate this possibility, 
we examined the IL-2 stimulated NK cells. As shown in 
Figure 5, (panel A and B), following a 10-day culture, 
IL-2 stimulated and resting LTNK cells were not 
significantly susceptible to ML-2 cell-induced NKCAs. 
In addition,TAPI-0 inhibited the down-regulation of 
CD16 on STNK cells, (Figure 5, panel C) and this effect 
was also detected when PBMCs cultured without IL-2 
were used as targets (Figure 5, panel D). Notably, TAPI-
0, at the concentration utilized did not alter the basal 
expression of CD16 and the percentage of NK cells. It 
reduced leukemia cell-induced CD16 down-regulation 
(Figure 5, panel E) and NK cell depletion (Figure 5, 
panel G) but did not affect leukemia cell-induced NK 
cell apoptosis (Figure 5, panel F). These results suggest 
that TIMP-3 inhibits ML-2 cell-induced CD16-down-
regulation and NK cell depletion but does not inhibit 
NK cell apoptosis.
Role of TIMP3 in LTNK cell resistance to AML 
cell-induced NKCAs
The ability of TAPI-0, to inhibit the induction of 
CD16-down-regulation and cell depletion by AML cells 
raised the possibility that TIMP3 may play a role in the 
resistance of LTNK cells to AML cell-induced NKCAs. 
To prove this possibility, we measured the expression 
level of TIMP3 gene and protein in LTNK cells. LTNK 
cells displayed levels of TIMP3 gene expression (Figure 
5, upper panel H) and protein shedding (Figure 5, lower 
panel H), in their culture supernatant, significantly higher 
than those found in STNK cells. Thus, in LTNK cells 
cultured at 37°C, the level of TIMP3 gene expression in 
NK cells was about 50 times higher than that in NK cells 
following a 3-day culture at 37°C. Similarly, following a 3 
and a 10-day culture at 37°C, NK cells produced 2192±69 
and 6963±59 pg/ml of soluble TIMP3, respectively. These 
Figure 4: Long-term cultured NK cells inhibit subcutaneous ML-2 cell growth in CB17 scid mice ML-2 cells (4 × 106) 
were mixed and injected subcutaneously, in the right flank of CB17 scid mice, without (N=8) or with 12 × 106 IL-2 stimulated STNK cells 
(N=4) or 12 × 106 IL-2 stimulated LTNK cells (N=4). Leukemia growth was monitored up to six weeks. Panel A. shows scatter plot analysis 
of tumor volumes of subcutaneous leukemia following a 37-day post injection. Panels B. and C. show DFS and OS, as indicated, in which 
CB17 scid mice were injected with ML-2 cells (dashed lines), ML-2 cells mixed with STNK cells,(dotted lines) and ML-2 cells mixed with 
LTNK cells (solid lines).
Oncotarget2075www.impactjournals.com/oncotarget
results suggest that TIMP3 is associated with the reduced 
susceptibility of LTNK cells to AML cell-induced NKCAs.
DISCUSSION
The results, we have described, indicate that AML 
cells induce abnormalities in a fraction of both CD16+ 
and CD16- NK cell-subsets. They include CD16 down-
regulation, NK cell apoptosis, and NK cell depletion. 
NKCAs are reversed by long-term culture of NK cells 
at 37°C; this is associated with an increased ability of 
LTNK cells to inhibit subcutaneous ML-2 cell growth, in 
CB17 scid mice, leading to a DFS and OS prolongation. 
The resistance to NKCAs by LTNK cell culture which 
involves RNA transcription is associated with TIMP3 
over-expression in vitro.
Our results show that STNK cells are not 
homogenously damaged by AML cells, but they 
harbour NK cell that are not damaged by AML cells. 
The identification of these cells is not readily apparent; 
although, their phenotypic and functional characterization 
may contribute to improving the therapeutic efficacy of 
immunotherapy of AML cells with NK cells.
In agreement with the results reported by Jewett 
et al. and by Grzywacz et al.[8, 11] we have found that 
leukemia cells cause CD16 down-regulation on STNK 
cells. This defect is likely to reflect MMP activation 
induced by NK cell-AML cell conjugation. As a result, 
CD16 antigen is trimmed and shed from NK cell surface.
[11] The key role of MMPs in the generation of this 
abnormality is also supported by the ability of MMP 
drug inhibitors to reverse the CD16 down-regulation in 
NK cells induced by leukemia cells and phorbol ester 
activation.[11, 17, 18] We have shown for the first time 
that biological MMP inhibitors such as TIMPs can inhibit 
CD16 down-regulation. We have focused our attention on 
TIMP3 because of its unique ability to induce apoptosis in 
normal and tumor cells in vitro.[19, 20]
CD16 antigen down-regulation is always associated 
with NK cell apoptosis and depletion. This association 
has been taken as evidence to suggest that CD16 antigen 
triggering plays a role in AML cell-induced NKCAs. 
In support of this possibility, a few studies have shown 
Table 1: Actinomycin D restores leukemia cell-induced NKCA in the long term-cultured NK cells
% of CD16 down 
regulation
3 days 10 days 10 days+actinomycin D
Exp 1:NK + ML-2 49 0 24
Exp 2:NK + ML-2 36 7 53
Exp 3:NK + ML-2 29 13 31
Exp 4:NK + ML-2 25 9 42
Statistics 34.7±10.5 7.2±5.4 37.5±12.7
% of NK cell frequency 
inhibition
3 days 10 days 10 days+actinomycin D
Exp 1:NK + ML-2 65 13 69
Exp 2:NK + ML-2 70 33 89
Exp 3:NK + ML-2 59 0 10
Exp 4:NK + ML-2 32 0 31
Statistics 56.5±16.9 11.5±15.5 49.7±35.7
Following a 3 day of stimulation with IL-2, aliquots of PBMCs were harvested and utilized for the assessment of NKCAs 
in the presence or absence of ML-2 cells. At the same time, actinomycin D (10 ng/ml) was added to the ongoing culture 
of PBMCs. On day 10, PBMCs were harvested and incubated for 18 hours in the presence or absence of ML-2 cells. 
NKCAs were evaluated by flow cytometry utilizing fluorescent conjugated anti-CD56, anti-CD16 and anti-CD3 mAbs. 
For statistical analysis: % of CD16 down-regulation and % of NK cell frequency inhibition were calculated by dividing 
CD16MFI and % of NK cell values obtained from PBMCs cultured in the presence of ML-2 cells by CD16 MFI and 
% of NK cells values obtained from PBMCs cultured in the absence of ML-2 cells x100 respectively. For CD16 down-
regulation we obtained: 3 days vs 10 days: P = 0.0035, 10 days vs 10 days + actinomycin D: P = 0.004, 3 days vs 10 
days+actinomycin D: P = 0.7. For % of NK cell frequency inhibition we had the following results: 3 days vs 10 days: 
P = 0.0079, 10 days vs 10 days + actinomycin D: P = 0.09, 3 days vs 10 days + actinomycin D: P = 0.7.
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that cross-linking of CD16 antigen by the corresponding 
mAbs induces NK cell apoptosis [12] and anergy in Fas+ 
NK cells. These cells, in the presence of endogenous 
TNF-α, undergo apoptosis that is inhibited, in vitro, by 
anti-TNF-α mAb; only a minor population of NK cells 
remains cytotoxic and proliferates in the presence of 
IL-2. These findings support a role for TNF-α in the 
induction of NK cell apoptosis.[21] To reinforce the role 
of CD16 in AML-induced NKCAs, we have shown that 
cross-linking of CD16 on NK cells by the Fc fragment 
of SY11B5, a mAb with specificity for CD157 antigen 
expressed on leukemia cells but not on NK cells, induces 
CD16 down-regulation and enhances NK cell apoptosis. 
However, neither FAS nor TNF-α death pathways seem 
to be involved in the induction of NK cell apoptosis 
and depletion since NKCAs are not affected by caspase 
blockade.[14] In addition, the CD56+CD16- NK cell 
subset undergoes AML cell-induced apoptosis to the same 
extent as the CD56+CD16+ NK cell subset. Furthermore, 
TAPI-0 reduced CD16 down-regulation and NK cell 
depletion but did not inhibit NK cell apoptosis suggesting 
that TIMP3 may not play a role in AML cell-induced NK 
cell apoptosis.
Because of the potential role of CD16 antigen in the 
generation of AML cell- induced NKCAs, we investigated 
whether the length of the in vitro incubation of NK cells 
with IL-2 causes changes in CD16 cell surface expression, 
STNK cells express a significantly higher CD16 expression 
Figure 5: Inhibition of AML cell-induced CD16-down-regulation and NK cell depletion by TAPI 0 defines a role 
for TIMP3 in the resistance of LTNK cells to AML-cell-induced NKCAs. Panels A. and B. Following a 10-day of culture, 
IL-2 (200 U/ml), post-activated and resting PBMCs were harvested and tested for NKCAs in the presence of ML-2 cells at a ratio of 1 
PBMC to 1 ML-2 cell. Following a 18-hour incubation, NK cells were analyzed for the expression of the indicated cell surface molecules 
by flow cytometry. Numbers included in the figure quadrants indicate CD16 MFI. Panel C. and D. Following a 3-day of culture, IL-2 
(200U/ml), post-activated and resting PBMCs were harvested and challenged with or without ML-2 cells. Left and right panels show the 
effects of TAPI-0 (10 mM) on CD16 cell surface expression of NK cells contained in PBMCs after 18 hours of culture in the presence 
or absence of ML-2 cells. Numbers in quadrants indicate CD16 MFI. This figure shows 1 representative experiment out of 3 performed 
with similar results. Following a 3-day of culture, IL-2 post-activated and resting PBMCs were harvested and incubated in the presence 
or absence of TAPI-0 and tested for NKCAs in the presence of ML-2 cells with or without TAPI-0 at a ratio of 1 PBMC to 1 ML-2 cell. 
Following an 18-hour incubation, NK cells were tested for CD16 expression panel E. apoptosis panel F. and NK cell depletion G. This 
figure shows a cumulative analysis of results obtained from 3 experiments independently performed. LD-PBLs enriched NK cells(>50% 
of CD3-CD56+CD16± cells) were grown in CM. At the indicated times, cells and culture supernatants were harvested. NK cells were 
further purified by magnetic sorting. Total RNA isolation and culture supernatants were utilized for the analysis of TIMP3 gene expression 
(upper panel H. and the assessment of soluble TIMP3 (lower panel H) respectively. Gene expression of TIMP3 was evaluated by q(RT)-
PCR utilizing beta-actin gene expression as a reference while soluble TIMP3 was measured by ELISA. This figure shows 1 representative 
experiment out of 3 performed with similar results.
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level than LTNK cells. The mechanism underlying this 
difference is not readily apparent. One might speculate 
that changes over time of CD16 expression on NK cells 
are independent of MPP inhibition by TIMP3.[22, 23] Two 
lines of evidence support this hypothesis. First, TAPI-0 
did not up-regulate CD16 expression on IL-2 stimulated 
STNK cells; second TAPI-0 decreased TIMP3 gene 
expression and protein secretion in IL-2 stimulated LTNK 
cells as compared to resting NK cells (data not shown). It 
is tempting to speculate that a population of NK cells with 
low or intermediate CD16 expression may be selected 
from a long-term NK cell culture. These results prompted 
us to test, in vitro and in vivo, the effect of AML cells on 
STNK and LTNK cells. LTNK cells become resistant to 
leukemia cell-induced NKCAs and this phenomenon is 
associated with an apparent anti-AML cell activity, in vivo, 
leading to AML cell growth inhibition in immunodeficient 
mice and, in vitro, TIMP3 over-expression in NK cells. 
It is important to highlight that subcutaneous injection 
of IL-2 stimulated STNK cells in the presence of ML-2 
cells, in CB17 scid mice, does not inhibit leukemia growth 
and has no effect on the clinical course of the disease. In 
this context, we can hypothesize that NKCA induced by 
ML-2 cells on STNK cells decreases their anti-leukemia 
potential.The lack of anti-leukemia activity of STNK 
cells, in vitro and in vivo, may reflect a reduction in the 
frequency of the functionally active NK cells due to the 
harmful effects of AML cells on STNK cells but not on 
LTNK cells. NKCA resistance to cancer cells became 
detectable following a 7-day culture and reached its peak 
on day 10 of NK cell culture. Based on this information 
one may speculate that the reduced expression of cell 
surface CD16 antigen may protect LTNK cells from AML 
cell-induced NKCAs. This kinetics is compatible with the 
possibility that changes in RNA transcription and protein 
synthesis are involved in the development of LTNK cell 
resistance to ML-2 cells. Indeed, LTNK cells cultured 
in the presence of actinomycin D for 10 days lost their 
resistance to ML-2 cells indicating that ML-2 cell-induced 
NKCAs involve RNA transcription.
TAPI-0 has inhibitory activity on a few MMPs 
including ADAM9, ADAM17, and MMP-1, 3, 9, and 13. 
[22, 23] Since TAPI-0 inhibited CD16 down-regulation 
and NK cell depletion, MMP inhibitors may be utilized 
to reduce STNK cell susceptibility to AML cell-induced 
NKCAs. On the other hand, Romee et al. demonstrated 
that a disintegrin and ADAM17 regulate CD16 expression 
on NK cells.[24] Furthermore, Wiernik et al. showed 
that ADAM17 inhibition enhances the cytotoxic activity 
of NK cells against myeloid leukemia cells by the anti-
CD16xanti-CD33 bispecific antibody. [25] The high 
resemblance of TIMP3 and TAPI-0 in their functional 
activity suggests that TIMP3 could play a role in the 
induction of the mechanism by which LTNK cells become 
resistant to AML cell-induced NKCAs. LTNK cells may 
acquire the ability to increase TIMP3 gene transcription 
and protein release in the culture supernatant. Then, 
soluble TIMP3 could interfere with MMP activation 
mediated by malignant cells.
Our data suggest that mechanism(s) underlying 
resistance of NK cells could be utilized to improve 
haploidentical or allogeneic LTNK and STNK-cell-based 
immunotherapy for hematological malignancies. In this 
context, the optimization of methodologies aimed at 
producing a good manufacturing practice expansion of 
LTNK cells may lead to their clinical implementation in 
the therapy of AML.[1–3] Also, the inhibition of AML 
cell-induced STNK cell abnormalities by drug mimicking 
the effects of TIMP3 such as TAPI-0[26] on STNK cells 
may allow STNK cells to be utilized to fight AML disease.
MATERIALS AND METHODS
Antibodies and reagents
Fluorescein isothiocyanate (FITC)-conjugated 
mouse anti-human-CD16, phycoerythrin-(PE)-conjugated 
anti-CD16, phycoerythrin-cyanine-dye5 (PE-Cy5)-
conjugated anti-CD3, allophycocyanin (APC)-conjugated 
anti-CD56, isotype-matched control monoclonal antibodies 
(mAbs) and FITC-annexin-V and propidium iodide (PI) 
were purchased from BD Bioscience (San Jose, CA). 
Anti-human CD157 (SY11B5) mAb was purchased from 
eBioscience (San Diego, CA). RPMI 1640 medium was 
purchased from Lonza (Milan, Italy). Recombinant IL-2 
was obtained from Chiron Corporation (Emeryville, CA).
Cell lines
The human myeloid leukemia cell lines ML-2, 
THP-1 and U937 were cultured in RPMI 1640 medium 
supplemented with 10% fetal bovine serum (FBS), 
glutamine (10 mg/ml), penicillin (10U/ml) and streptomycin 
(10 mg/ml). Cells are part of our cell line laboratory 
collection. The identity of the ML-2 and U937 cell lines is 
monitored by a phenotypic analysis of cell surface markers. 
The latter is identified as CD45+HLA-A2-chondroytin 
sulphate proteoglycan (CSPG) 4+ while the former is 
identified as CD45+HLA-A2+CSPG4+. The identity of 
the THP-1 cells is monitored by the analysis of cell surface 
expression of CD45 and Fc receptor and by HLA class II 
allele genotyping including DRW1 and DRW2.
Isolation of peripheral blood mononuclear cells 
(PBMCs)
PBMCs isolated by Ficoll-Hypaque density 
gradient centrifugation from buffy coats obtained from 
the University of Tor Vergata Blood Bank donors. Low-
density peripheral blood lymphocytes (LD-PBLs) were 
isolated as previously described.[13] PBMCs and LD-
PBLs were activated with IL-2 (200 U/mL) for 3-16 days 
at 37°C in RPMI 1640 medium supplemented with 10% 
FBS; this medium is referred to as a complete medium 
(CM). CD56+ cells and NK cells were isolated utilizing 
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anti-CD56 magnetic beads and the NK cell isolation kit, 
respectively (Miltenyi Biotec, Auburn, CA).
Flow cytometry analysis
PBMCs or magnetically sorted CD56+ cells were 
mixed with leukemia cells at different E/T ratio. Following 
a 5-18-hour incubation at 37°C in a 5% CO2 atmosphere, 
cells were harvested, incubated for 30 min at 4°C with PE-
conjugated anti-CD16 mAb, PE-Cy5-conjugated anti-CD3 
mAb, APC-conjugated anti-CD56 mAb, Then, cells were 
incubated for 15 min at room temperature, in the dark, 
with FITC-annexin-V and analyzed as already described.
[14] Results were analyzed utilizing the BD Cell Quests 
and the Tree Star Inc. flowJo software.
Cytotoxicity assay
The standard 51Cr-release cytotoxicity assay was 
performed as described.[15] Maximum Cr release was 
measured by incubating target cells with 5% triton-X-100. 
Percent of specific lysis was calculated utilizing the 
formula: (experimental release-spontaneous release) / 
(maximum release-spontaneous release) × 100. The 
spontaneous release was less than 10%.
Mice
Ten-week-old male CB17 SCID mice were purchased 
from Charles River Laboratories (Lecco, Italy) and housed 
in laminar flow cages. Mice were fed with sterile food 
and water. Mouse age at the beginning of the experiments 
ranged between 20-22 weeks. Mice endogenous NK cell 
activity was inhibited by an intraperitoneal injection of 
50 ml of anti-asialo GM1 antiserum (Wako, Chemicals, 
Richmond, VA,) on day -3, 0, +14 and +21 utilizing as a 
reference time that of a subcutaneous injection of ML-2 
cells or ML-2 plus NK cells.
In vivo anti-leukemia activity of short term and 
long term NK cells
PBMCs were cultured in CM at 37°C. Following 
a 3-day and a 10-day culture, PBMCs were harvested, 
and NK cells were negatively sorted (95% purity). Then 
ML-2 cells (4 × 106) were mixed with 3-day cultured NK 
cells (12 × 106), or with 10-day cultured NK cells (12 × 
106), hereafter referred to as short term NK (STNK) 
cells, and long-term NK (LTNK) cells, respectively. Cell 
mixtures were resuspended in PBS supplemented with 
matrigel (Corning, Tewksbury, MA). Following a 30-min 
incubation at 37°C, 4 mice were injected with an ML-2-
STNK cell suspension and 4 with an ML-2-LTNK cell 
suspension. Eight mice were injected with an ML-2 cell 
suspension and used as a control. Subcutaneous ML-2 
cell growth was monitored 3 times weekly with calipers. 
Tumor volume (TV) was calculated using the formula: TV 
(cm3)=4/3p r3, where r=(length + width)/4. When tumor 
volume exceeded 2 cm3, a mouse was sacrificed.
Gene expression analysis
Following TRIzol based isolation (Life Technologies 
Italia, Monza, Italy) from cells, total RNA was subjected to 
reverse transcription using M-MLV reverse transcriptase 
(Invitrogen, Carlsbad, CA). Quantitative RT-PCR of 
TIMP3 and β-actin was performed using the TaqMan 
universal PCR master mix. Primers and probes of TIMP3 
were purchased, from Life Technologies (Carlsbad, 
CA) as a kit assay product, Hs00165949_m1 (TIMP3). 
Gene expression was quantified as previously described.
[16] Gene expression was normalized on the b-actin 
housekeeping gene.
Statistical analysis
Results were analyzed using a Mann-Whitney test 
or a paired-T-test. DFS and OS results were evaluated by 
a Kaplan-Meyer analysis. Differences were considered 
significant when the p value was < 0.05.
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